Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.
One of our most popular services, Zacks Premium offers daily updates of the Zacks Rank and Zacks Industry Rank; full access to the Zacks #1 Rank List; Equity Research reports; and Premium stock screens like the Earnings ESP filter. All are useful tools to find what stocks to buy, what to sell, and what are today's hottest industries.
Also included in Zacks Premium is the Focus List. This is a long-term portfolio of top stocks that have all the traits to beat the market.
Breaking Down the Zacks Focus ListIf you could get access to a curated list of stocks to kickstart your investment portfolio, wouldn't you jump at the chance to take a peek?
Enter the Zacks Focus List. It's a portfolio made up of 50 stocks that are set to beat the market over the next 12 months; each company selected serves as a foundation for long-term investors looking to create an individual portfolio.
One thing that makes the Focus List even more advantageous is that each pick comes with a full Zacks Analyst Report. This helps explain why each stock was selected and why we believe it's a good pick for the long-term.
The portfolio's past performance only solidifies why investors should consider it as a starting point. For 2020, the Focus List gained 13.85% on an annualized basis compared to the S&P 500's return of 9.38%. Cumulatively, the portfolio has returned 2,519.23% while the S&P returned 854.95%. Returns are for the period of February 1, 1996 to March 31, 2021.
Focus List MethodologyWhen stocks are picked for the Focus List, it reflects our enduring reliance on the power of earnings estimate revisions.
Earnings estimates, or expectations of growth and profitability, come from brokerage analysts who track publicly traded companies; these analysts work together with company management to analyze every aspect that may affect future earnings, like interest rates, the economy, and sector and industry optimism.
Earnings estimate revisions are very important, since investors also need to take into consideration what a company will earn in the future.
The stocks that receive positive changes to earnings estimates are more likely to receive even more upward changes in the future. Take this example: if an analyst raised their estimates last month, they'll probably do so again this month, and other analysts will follow.
Utilizing the power of earnings estimate revisions is when the Zacks Rank joins the party. A unique, proprietary stock-rating model, the Zacks Rank uses changes to quarterly earnings expectations to help investors create a winning portfolio.
The Zacks Rank consists of four main pillars: Agreement, Magnitude, Upside, and Surprise. Each one is given a raw score, which is recalculated every night and compiled into the Rank. Then, stocks are classified into five groups, ranging from "Strong Buy" to "Strong Sell," using this data.
The Focus List is comprised of stocks hand-picked from a long list of #1 (Strong Buy) or #2 (Buy) ranked companies, meaning that each new addition boasts a bullish earnings consensus among analysts.
It can be very profitable to buy stocks with rising earnings estimates, as stock prices respond to revisions. By adding Focus List stocks, there's a great chance you'll be getting into companies whose future earnings estimates will be raised, which can lead to price momentum.
Focus List Spotlight: Micron (MU - Free Report) Idaho-based Micron Technology has established itself as one of the leading worldwide providers of semiconductor memory solutions.
MU, a #1 (Strong Buy) stock, was added to the Focus List on December 27, 2016 at $23.26 per share. Since then, shares have increased 4577.52% to $1.
Six analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $1.87 to $60.23. MU also boasts an average earnings surprise of 21.7%.
Additionally, MU's earnings are expected to grow 626.5% for the current fiscal year.
Reveal Winning StocksUnlock all of our powerful research, tools and analysis, including the Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. You'll quickly identify which stocks to buy, hold and sell, and target today's hottest industries, to help improve the performance of your portfolio. Gain full access now >>
The AI boom has created a small group of companies that sit at the center of an enormous spending wave. Most investors immediately think of Nvidia (NASDAQ:NVDA | NVDA Price Prediction) when they hear that story. Yet memory chips have quietly become just as critical to AI infrastructure as GPUs.
Every AI server requires massive amounts of DRAM and high-bandwidth memory (HBM), and supply remains tight even after a year of record production. That shift has transformed Micron Technology (NYSE:MU) from a cyclical memory manufacturer into one of the market’s biggest AI winners. The stock has already delivered extraordinary gains, but Wall Street believes the story may not be finished.
An 811% Gain Doesn’t Mean The Opportunity Is Gone Micron opened trading on this date one year ago at approximately $118 per share. Twelve months on and the stock trades around $1,075, an 811% return that turned a $10,000 investment into more than $91,000.
Most investors would assume that kind of move leaves little upside remaining. TD Cowen disagrees. The firm raised its price target on Micron to $1,500 from $660 while maintaining its Buy rating. That target implies roughly 40% upside from current levels. The firm’s analyst team pointed to stronger-than-expected AI demand and a longer period of favorable memory pricing as the key drivers behind the increase.
Notably, TD Cowen is not alone. Cantor Fitzgerald also carries a $1,500 target, while Susquehanna has gone even higher with a $1,750 target.
mu
The Memory Cycle Looks Different This Time Memory has historically been one of the semiconductor industry’s most cyclical businesses. Prices rise, manufacturers expand capacity, supply catches up, and prices fall. That’s the pattern investors have seen for decades.
The current cycle contains two key differences. First, TD Cowen now expects pricing strength to extend through the second half of 2027. Previously, analysts expected a digestion period to begin during the first half of 2027, but stronger CPU demand and continued AI infrastructure deployments have pushed that timeline further out.
Second, analysts increasingly view AI as a structural shift rather than a temporary demand surge.
A cyclical upswing eventually returns to prior demand levels. A structural shift, though, raises the baseline. AI data centers need dramatically more memory per server than traditional computing workloads. Even if growth slows, the floor for future demand may remain far above where it stood before the AI era.
Bank of America recently argued that memory supply elasticity is structurally lower because of capital, packaging, and power constraints across the industry. Simply, supply can’t respond as quickly as it did during prior cycles.
Micron’s Competitive Position Keeps Improving Only three companies produce advanced memory at scale: Micron, SK hynix, and Samsung. Micron trails its industry peers — not by much, in some sectors — but that concentrated industry structure gives Micron more pricing power than it enjoyed in past cycles.
Management has also been signing longer-term customer agreements, creating greater revenue visibility than memory investors traditionally received. Analysts estimate Micron could generate approximately $150 per share in earnings during 2027 if current trends continue.
Surprisingly, Micron still trades at valuation levels that assume memory remains highly cyclical. Several analysts argue that if AI-driven demand proves more durable, investors may continue assigning a higher earnings multiple to the stock.
Key Takeaway In short, Micron’s 811% gain over the past year doesn’t automatically mean the opportunity has passed.
The bull case rests on two simple ideas: memory pricing may remain strong longer than expected, and AI has permanently increased demand for advanced memory products. TD Cowen’s new $1,500 price target reflects both assumptions.
Granted, memory remains a cyclical industry beyond AI and investors should expect volatility. Yet Micron today looks very different from the commodity memory company many investors remember. With AI servers consuming unprecedented amounts of DRAM and HBM, the company has become a critical supplier to one of the fastest-growing technology markets in history.
If Wall Street’s forecasts prove accurate, Micron’s remarkable run may have another chapter left to write.
Shares of Micron Technology, Inc. (NASDAQ:MU) are moving lower on Tuesday. They have gained almost 300% since January 1.
Micron is the Stock of the Day. It appears to be breaking out again. The rally may continue.
If a stock is trending higher, there is more demand for it than there is supply. Investors and traders who wish to acquire shares are forced to outbid each other and pay premiums to attract sellers.
This forces the shares into an uptrend.
The dynamic changes when the shares reach a resistance level. At these levels, there is enough supply of shares for sale to fill all buy orders. Buyers can acquire all the shares they need to without paying higher prices, and the rally ends or pauses.
Sometimes stocks reverse and head lower after reaching resistance.
This happens when some of the sellers who created the resistance become anxious and impatient. They become concerned that other sellers will be willing to sell at lower prices.
They know the buyers will go to whoever is willing to sell at the lowest price. As a result, they reduce their offer prices. Other concerned sellers see this and do the same.
This can result in a snowball effect that pushes the price lower.
Sometimes when stocks reach resistance, the buyers eventually overpower the sellers, and the price moves higher. When this happens, traders say it is a ‘breakout'.
Breakouts can be a bullish dynamic. They show that the sellers who created the resistance are gone. With this supply removed from the market, buyers will be forced to outbid each other again. This can put the shares into a new uptrend.
As you can see on the chart, Micron broke out in April. It also broke out in May. A move higher followed each.
The stock had been attempting to break out, but as of Tuesday’s pullback, it remains below resistance around $1,090. Micron will need to clear that level to confirm a new uptrend.
MU Price Action: Micron Technology shares were down 4.05% at $1043.91 at the time of publication on Tuesday, according to Benzinga Pro data.
Photo: Shutterstock
Market News and Data brought to you by Benzinga APIs
In the latest trading session, Micron (MU - Free Report) closed at $1,020.76, marking a -6.18% move from the previous day. This change lagged the S&P 500's 0.57% loss on the day. On the other hand, the Dow registered a gain of 0.64%, and the technology-centric Nasdaq decreased by 1.15%.
Prior to today's trading, shares of the chipmaker had gained 59.64% outpaced the Computer and Technology sector's gain of 2.85% and the S&P 500's gain of 2.14%.
The investment community will be paying close attention to the earnings performance of Micron in its upcoming release. The company is slated to reveal its earnings on June 24, 2026. The company is forecasted to report an EPS of $19.72, showcasing a 932.46% upward movement from the corresponding quarter of the prior year. Meanwhile, our latest consensus estimate is calling for revenue of $34.24 billion, up 268.09% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of $60.23 per share and a revenue of $111.55 billion, demonstrating changes of +626.54% and +198.45%, respectively, from the preceding year.
Investors should also note any recent changes to analyst estimates for Micron. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 2.43% increase. Micron is currently a Zacks Rank #1 (Strong Buy).
Looking at its valuation, Micron is holding a Forward P/E ratio of 18.07. This signifies a discount in comparison to the average Forward P/E of 27.36 for its industry.
The Computer - Integrated Systems industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 14, which puts it in the top 6% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Few corners of the market have run up as sharply as memory chips. Shares of Sandisk (SNDK 5.39%) have soared more than 700% in 2026 as of this writing, while Micron Technology (MU 5.50%) has more than tripled this year and recently crossed $1 trillion in market value. Both have climbed for the same reason: an artificial intelligence (AI) build-out so hungry for storage and memory that supply can't keep up, pushing prices for NAND flash and dynamic random access memory (DRAM) sharply higher.
But which of these two stocks is the better buy today?
Image source: The Motley Fool.
Sandisk: a pure bet on the flash shortage In its fiscal third quarter of 2026 (the period ended April 3, 2026), the flash specialist's revenue jumped 97% from the prior quarter and 251% from a year earlier, to $5.95 billion. Non-GAAP (adjusted) earnings per share reached $23.41, up from $6.20 in fiscal Q2.
Powering its growth, Sandisk's data center revenue climbed 233% sequentially.
Today's Change
(
-5.39
%) $
-113.58
Current Price
$
1994.28
What may matter more for a notoriously cyclical business is how much of that demand Sandisk has nailed down. Fortunately, it has signed five multiyear supply agreements that lock in firm customer commitments, covering more than a third of its fiscal 2027 output and backed by over $11 billion in enforceable financial guarantees.
"Data center has become our fastest-growing market, and the workloads driving that demand, including inference, reasoning, and agentic systems, represent a structural and durable shift in how the world's most consequential technology is built and deployed," said Sandisk CEO David Goeckeler in the company's fiscal third-quarter earnings call.
Sandisk is also returning cash to shareholders. It recently authorized a $6 billion share buyback. And it carries no debt.
Micron: the broader memory play Micron's momentum is similarly spectacular. In its fiscal second quarter of 2026 (the period ended Feb. 26, 2026), the memory and storage maker posted revenue of $23.86 billion, nearly triple the year-ago figure, with adjusted earnings per share of $12.20 and a record gross margin of about 75%. DRAM made up $18.8 billion of that, or 79% of revenue, while NAND accounted for the rest.
Within its DRAM business, HBM -- the dense, stacked chips that pair with AI accelerators from the likes of Nvidia -- is the scarcest, highest-value product in the memory market, and Micron has said its HBM output for 2026 is already sold out.
Today's Change
(
-5.50
%) $
-59.79
Current Price
$
1028.20
And the company notably began shipping its newest HBM for Nvidia's next-generation Vera Rubin platform earlier this year.
"Both AI and traditional server demand are constrained by lack of adequate DRAM and NAND supply," said Micron CEO Sanjay Mehrotra in the company's fiscal second-quarter earnings call.
Looking ahead, Micron is guiding for an even bigger fiscal third quarter, with revenue of about $33.5 billion -- a single quarter that would exceed its revenue for any full year through fiscal 2024.
But this growth story comes with high costs. Micron expects to spend more than $25 billion on new plants and equipment this fiscal year.
On valuation, Sandisk initially looks more expensive, with a price-to-earnings ratio of about 69 as of this writing, while Micron's is 49. But these valuation metrics don't tell the full story. Since the two companies are growing so quickly, it's probably better to view them based on their forward price-to-earnings ratios, or valuation multiples that compare their prices to analysts' consensus forecasts for earnings per share over the next 12 months. By this measure, Sandisk and Micron have forward price-to-earnings multiples of about 11 and 10, respectively, making them look priced very similarly based on their future prospects.
So, which is the better buy?
Overall, I think Micron is the better bet. Its DRAM and HBM exposure puts it in a vital part of the AI memory market, and it generates enormous cash even while funding a heavy build-out. Meanwhile, Sandisk's business is arguably narrower than Micron's, leaving it with greater downside risk if the cycle turns. And after a run-up this big, I'd rather own the broader business.
SummaryMicron is experiencing unprecedented demand for DRAM, NAND, HBM, and enterprise SSDs, driving record revenue and gross margins.MU's supply-demand imbalance is expected to persist beyond 2026, supported by Strategic Customer Agreements that enhance earnings visibility and pricing power.Consensus estimates for MU's FY26 and FY27 earnings are likely too conservative, with forward P/E potentially overstated and substantial upside remaining.I rate MU a Buy, citing derisked cyclicality, strong operating leverage, and favorable long-term demand trends despite execution and pricing risks. Alexander Sikov/iStock via Getty Images
Introduction Micron (MU) has historically been treated as a deeply cyclical memory stock, but the current cycle looks materially different. AI-driven demand for DRAM, NAND, HBM, and enterprise SSDs has created insatiable demand for MU
148 Followers
Analyst’s Disclosure: I/we have a beneficial long position in the shares of MU either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Ken Griffin, the billionaire CEO of the investment firm Citadel Advisors, has an impeccable reputation on Wall Street, having delivered superior returns over the long run. It's no wonder, then, that every move he and his team make is carefully scrutinized. And he was a busy man during the first quarter. Citadel Advisors decreased its stake in some popular artificial intelligence (AI) stocks. The firm sold 2.9 million shares of Nvidia (NVDA 2.16%), while offloading six million shares of Amazon (AMZN 0.01%).
Both tech leaders remain among Citadel Advisors' largest holdings, but perhaps the decision to reduce its stake in these companies was to reallocate capital into attractive opportunities. And one notable stock that Citadel Advisors bought during the quarter looks like such an opportunity.
Image source: The Motley Fool.
A beaten-down healthcare leader Intuitive Surgical (ISRG +0.17%) has lagged the market recently. The company is dealing with headwinds from multiple sources. Let's consider three of them. First, Intuitive Surgical will face increased competition in the robotic-assisted surgery (RAS) market moving forward. Last year, Medtronic earned approval for a competing system, the Hugo, while Johnson & Johnson is also racing toward clearance of its own device, the Ottava.
Second, several of Intuitive Surgical's products, including its da Vinci 5 -- the newest model of its famous, market-leading da Vinci system -- carry lower margins than the company's average. Selling more of these platforms can drag down margins, at least in the short term. Third, steep tariffs have impacted Intuitive Surgical's financial results. Because of all these factors -- and despite pretty strong financial results -- the stock has dropped by 20% over the past 12 months.
There is more to the story Given all the problems Intuitive Surgical is facing, why did Citadel Advisors take this opportunity to increase its stake in the company by 30.3% during the first quarter? One likely answer is that, despite the medical device specialist's struggles, its long-term prospects remain bright, and it could deliver superior returns, especially at current levels. None of Intuitive Surgical's obstacles is anywhere near insurmountable.
Yes, competition will increase, but the company has a massive lead, having spent the past 26 years since the da Vinci system was first launched expanding its installed base, improving patient outcomes, and gathering real-world data from procedures to inform its device development.
Today's Change
(
0.17
%) $
0.72
Current Price
$
417.27
Further, Intuitive Surgical benefits from a wide moat due to high switching costs, and the company still has a massive addressable market to tap into. It's also worth noting that it could be one of the winners as AI continues to transform the healthcare sector. Intuitive Surgical is actively exploring ways to use AI to improve its technology, which could help cement its leading position in its niche over the long run.
How will the company address lower margins on some of its devices? Those should pay for themselves several times over, eventually. Absorbing lower margins in the early stages of scaling a new device helps the company grow its installed base and eventually results in stronger revenue and earnings from the sale of instruments and accessories, which are replaced regularly and generate recurring, higher-margin revenue for the healthcare giant. So, this strategy is well worth it.
And as far as tariffs are concerned, Intuitive Surgical can deal with them eventually through modest cost increases across its large pool of existing customers, most of whom should stay put, given the few alternatives to Intuitive Surgical's devices on the market.
Looking at the valuation The bears would also point out that Intuitive Surgical still looks expensive, trading at 39.7x forward earnings, more than twice the healthcare sector's average of 17.4x. Even so, Intuitive Surgical continues to grow its revenue and earnings much faster than most of its peers, especially those in the medical device niche. Further, the company's large addressable RAS market and strong competitive edge help justify a steep premium. My view is that Intuitive Surgical is a strong buy after having lost significant value over the past year.
Prosper Junior Bakiny has positions in Amazon, Intuitive Surgical, Johnson & Johnson, and Nvidia. The Motley Fool has positions in and recommends Amazon, Intuitive Surgical, Medtronic, and Nvidia. The Motley Fool recommends Johnson & Johnson and recommends the following options: long January 2028 $520 calls on Intuitive Surgical and short January 2028 $530 calls on Intuitive Surgical. The Motley Fool has a disclosure policy.
AMC Entertainment shares are climbing with conviction. What’s fueling AMC momentum? What Is Driving AMC’s Recent Capital Raise?AMC said it completed its previously announced $150 million at-the-market equity offering, selling about 105.3 million shares and raising the full amount. Management framed the proceeds as a way to strengthen cash, improve financial flexibility, and support priorities like boosting Adjusted EBITDA and reducing leverage.
AMC is also leaning on industry and operating momentum, citing a record May box office and six films with domestic opening weekends above $75 million over the past 11 weeks. The company previously said May attendance reached 25.5 million guests globally, its strongest May since 2019, reinforcing the "demand is recovering" message behind the capital raise.
Critical Price Levels To Watch For AMCFrom a longer-term chart perspective, AMC is in a rebound phase: at $2.36 it's trading well above its 20-day ($1.81), 50-day ($1.63), and 200-day ($1.90) moving averages, which often acts like "trend confirmation" after a basing period. The catch is the bigger-picture trend is still repairing, with the 50-day SMA still below the 200-day SMA (a bearish longer-term structure that can cap rallies).
Momentum is improving: MACD is above its signal line and the histogram is positive, which typically means upside pressure is building versus the prior downswing rather than fading. MACD compares shorter- and longer-term trend forces and being above the signal line suggests buyers are gaining control of the near-term tape.
The equity-offering headline also matters technically because supply can become an overhang after sharp runs, so bulls usually want to see price hold above the 200-day area on pullbacks. Key longer-term context: the stock's recent swing low formed in March (near the 52-week low of 93 cents), while the last swing high was in June, leaving a wide trading range that can stay choppy.
Key Resistance: $2.50 — lines up with a round-number area near the Street's high target and a likely supply zone after the recent run Key Support: $1.90 — near the 200-day SMA/EMA zone ($1.90–$1.92), a common "line in the sand" in trend repairs What Is AMC Entertainment Holdings?AMC Entertainment Holdings is in the theatrical exhibition business, owning and operating theaters across the U.S. and Europe, with the U.S. as its main revenue driver. It also leans on premium formats and in-theater amenities like plush recliners, MacGuffins full bars, and AMC Dine-In locations to lift per-guest spending.
That backdrop ties directly to the current narrative: AMC is pointing to improving industry demand (including a record May box office and multiple $75 million-plus domestic opening weekends recently) while raising capital to shore up liquidity. For a company where leverage and cash runway have been recurring investor focus points, funding moves like this can quickly become the main driver of near-term trading.
AMC Stock Price Movement on TuesdayAMC Stock Price Activity: AMC Entertainment shares were up 4.39% at $2.38 at the time of publication on Tuesday, according to Benzinga Pro data.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
June 16, 2026 16:05 ET | Source: AMC Global Media Inc.
NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- AMC Global Media Inc. (NASDAQ: AMCX) announced Hozefa Lokhandwala has joined the company as Chief Financial Officer, effective today. Lokhandwala joins AMC Global Media with more than two decades of financial leadership experience across media, corporate strategy and investment banking. He will be based in New York and will report to AMC Global Media’s CEO Kristin Dolan.
“Hozefa is a highly respected and accomplished media executive with the financial discipline, industry expertise and strategic perspective to help guide AMC Global Media during this dynamic period in our industry,” said Dolan. “We look forward to benefiting from his leadership and experience as we continue to advance our strategic priorities and position the company for long-term success.”
“AMC Global Media is behind some of my favorite television shows of all time, and I have long admired its rare combination of celebrated storytelling, valuable IP and disciplined strategic focus,” said Lokhandwala. “I’m thrilled to join Kristin and the leadership team at this exciting moment and to help leverage the company’s strong collection of assets as it continues to build on its momentum.”
Lokhandwala most recently served as an Independent Director for MSG Networks. Prior to MSG Networks, he worked at Vice Media Group serving as Co-Chief Executive Officer after joining as Chief Strategy Officer in 2018.
Earlier in his career, Lokhandwala served as a Managing Director in the Media Investment Banking Group at J.P. Morgan, where as Head of Content & Entertainment Investment Banking he advised media clients on mergers and acquisitions, capital markets and corporate finance matters across diversified media, programming networks, film and entertainment, gaming, music and digital media. Before joining J.P. Morgan, he was an investment banker in the Media & Entertainment Group at Bear Stearns and also worked in the Business & Finance group at Morgan Lewis, advising on M&A and finance transactions. He holds an MBA from Columbia Business School, a JD from Brooklyn Law School and a BA from Oberlin College. He also serves on the Board of Trustees for Oberlin College, including as Chair of the Risk Management & Audit Committee.
Lokhandwala succeeds Patrick O’Connell, the company’s former Chief Financial Officer who stepped down in March as part of a planned departure announced in January.
The appointment comes as AMC Global Media continues to build momentum across its business. The company recently reported another quarter of double-digit streaming revenue growth and robust free cash flow, highlighting continued progress across its targeted streaming portfolio which is now the company’s largest source of domestic revenue. The company also continues to build on the strength of its owned franchises and fan-focused strategy, including the recent premiere of Anne Rice’s The Vampire Lestat on AMC and AMC+, which generated strong early audience engagement and critical acclaim, further demonstrating the company’s ability to create high-quality, franchise-driven programming with broad cultural resonance.
About AMC Global Media
AMC Global Media is the ultimate destination for premier storytelling, known for some of the most celebrated original content in television and film history. The Company creates and curates celebrated series and films across distinct brands and makes them available to audiences everywhere. Its portfolio includes targeted streaming services AMC+, Acorn TV, Shudder, Sundance Now, ALLBLK, HIDIVE and ALL REALITY; cable networks AMC, BBC AMERICA, IFC, SundanceTV and We TV; film distribution labels Independent Film Company and RLJE Films; AMC Studios, its in-house studio, production and distribution operation; and AMC Networks International, its international programming business.
BlackBerry UEM advances AI-assisted operations and post-quantum readiness while strengthening data residency and cloud independence with expanded macOS support for enterprise, defense and governments
WATERLOO, ON / ACCESS Newswire / June 16, 2026 / BlackBerry Secure Communications, a division of BlackBerry Limited (NYSE:BB)(TSX:BB), today announced enhanced capabilities coming to BlackBerry® Unified Endpoint Management (UEM) designed to meet growing demand for sovereign endpoint control across enterprise, government, and regulated industries.
Sovereign control over endpoints is becoming a mainstream requirement well beyond traditional regulated sectors, driven by tightening data-residency requirements across Europe, finalized post-quantum cryptography standards, and accelerating adoption of Apple devices in environments that cannot route management through a public cloud. The upcoming UEM release extends the BlackBerry platform's sovereign endpoint management capabilities across AI-assisted operations, post-quantum cryptography, macOS, multi-tenant environments and secure file sharing.
"Organizations should not have to choose between modern capabilities and sovereign control," said Nathan Jenniges, Senior Vice President and General Manager, BlackBerry Secure Communications. "These enhancements enable customers to adopt AI, prepare for the post‑quantum era, and manage diverse device fleets on infrastructure they own and control."
As enterprises and governments expand macOS deployments, many endpoint management solutions remain tethered to vendor‑hosted clouds, introducing jurisdictional exposure that European and public‑sector buyers are actively designing out of their environments.
BlackBerry is expanding macOS management within UEM through its on‑premises deployment model, enabling organizations to manage Apple, Windows and Android devices from a single console without cloud dependency or third‑party data paths. BlackBerry UEM is the first and only endpoint management solution certified by Germany's Federal Office for Information Security under Common Criteria, validated for managing Apple and Samsung devices in government environments.
To address emerging cryptographic risks, BlackBerry UEM is advancing its post‑quantum roadmap by upgrading cryptographic libraries on devices and aligning with NIST post‑quantum standards as part of its path toward FIPS 140‑3 accreditation. These enhancements embed quantum‑resistant protections from the UEM server through to secured applications on end‑user devices. Combined with UEM's BSI Common Criteria certification and NATO Restricted alignment, this provides regulated buyers in Europe and beyond with a migration path grounded in independently validated credentials rather than reliance on a single national standard.
The release also introduces expanded multi‑tenant management capabilities to support service providers and complex enterprise and government estates that require strong separation between departments, agencies or customers. A modernized UEM console and refreshed administrator experience reduce operational complexity while supporting scale in sovereign, on‑premises environments.
Secure AI-assisted capabilities are optional and can be enabled at an organization's discretion, improving efficiency while operating within BlackBerry's security first architecture and under organizational control. Rounding out the release, enhancements to BlackBerry's secure file-sharing capability embed access controls directly into each document, so protection travels with the file itself rather than depending on a network perimeter, addressing exfiltration risk in zero-trust environments.
The new capabilities are expected to be available in the summer of 2026, with select management and multi‑tenant console enhancements becoming generally available later in 2026. To learn more about the latest BlackBerry UEM enhancement, read the blog.
###
About BlackBerry
BlackBerry (NYSE:BB)(TSX:BB) provides enterprises and governments the intelligent software and services that power the world around us. Based in Waterloo, Ontario, the company's high-performance foundational software enables major automakers and industrial giants alike to unlock transformative applications, drive new revenue streams and launch innovative business models, all without sacrificing safety, security, and reliability. With a deep heritage in Secure Communications, BlackBerry delivers operational resiliency with a comprehensive, highly secure, and extensively certified portfolio for mobile fortification, mission-critical communications, and critical events management.
For more information, visit BlackBerry.com and follow @BlackBerry.
Teladoc (TDOC - Free Report) ended the recent trading session at $7.57, demonstrating a +1.47% change from the preceding day's closing price. This move outpaced the S&P 500's daily loss of 0.57%. Meanwhile, the Dow experienced a rise of 0.64%, and the technology-dominated Nasdaq saw a decrease of 1.15%.
The telehealth services provider's stock has climbed by 17.48% in the past month, exceeding the Medical sector's gain of 4.28% and the S&P 500's gain of 2.14%.
Market participants will be closely following the financial results of Teladoc in its upcoming release. The company is expected to report EPS of -$0.24, down 26.32% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $614.69 million, indicating a 2.72% downward movement from the same quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.92 per share and a revenue of $2.51 billion, representing changes of +19.3% and -0.92%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Teladoc. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.97% higher within the past month. Teladoc currently has a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 109, placing it within the top 45% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Zillow's 2026 paint color analysis finds warm, nature-inspired tones drive higher offers, while one trendy color can wipe out $18,000 in home value
A warm chocolate brown bedroom can add nearly $2,300 to a home's offer price. Sage green is the only color to rank in the top tier across every room. Ochre yellow painted throughout a home can shave $18,164 off a home's value. , /PRNewswire/ -- Chocolate brown is back, and this time it's worth thousands. Painting a bedroom chocolate brown can add $2,277 to a home's offer price, according to Zillow's 2026 Paint Color Analysis. It's the highest-value interior color choice in this year's study.
Zillow® research finds that today's buyers are drawn to warm, grounded interiors over all-white walls. In the living room, pale blue commands $1,723 more than white, and charcoal gray $1,509 more. In the bedroom, it's not just chocolate brown that beats white. Charcoal gray also commands higher offers, by $1,240, and sage green tops white by $1,035.
"White will always be a timeless, versatile choice, but sellers who default to all-white walls everywhere may be leaving money on the table," said Amanda Pendleton, Zillow's home trends expert. "Buyers today respond to homes with soul, and paint is one of the easiest, most affordable ways to add personality and character to a space. The right colors can stop a shopper mid-scroll and instantly create an emotional connection, which ultimately drives higher offers. If a seller were to repaint the top performing color in each room, they could add more than $5,000 to their bottom line."
Sage green is the new white
Sage green emerges as the standout performer of 2026. It is the only color to rank in the top tier across every single room, scoring high points from buyers for the bathroom, living room and bedroom. This easy-to-live-with earth tone is the safest bet across the board. When painted in the bedroom, sage green could add more than $1,000 to offer prices; in the living room, nearly $500.
Dark and moody kitchens deliver real ROI
The moody kitchen trend is here to stay. Homes with charcoal gray and dark plum kitchens may get the highest offers, commanding an additional $1,373 and $867 respectively. If a seller can only repaint one room, the data points clearly to the kitchen: The range between the best and worst colors is nearly $8,000 (from charcoal gray at +$1,373 to ochre yellow at −$6,630), making it the highest-stakes room for color decisions.
The $18,000 mistake to avoid
The wrong colors carry real consequences. Ochre yellow is the single worst color a seller can paint their interior walls and may shave an estimated $18,164 off a home's offer price when painted in the kitchen, living room, bedroom and bathroom. When painted in the kitchen alone, this shade of dark gold could reduce offers by $6,630.
Buyers may also offer nearly $8,000 less for homes with a bathroom painted fire-hydrant red. Pale pink ranks in the bottom three for every room, too, potentially costing sellers $6,013 in the bathroom and $4,201 in the kitchen.
The bottom line for sellers
Before pulling out the drop cloth and paint roller, homeowners should consult with a trusted local real estate agent for advice on what buyers are looking for in their particular neighborhood. The right paint color is a strong start, but savvy sellers pair it with a broader strategy:
Test the market before going live. Zillow Preview℠ lets sellers introduce a home to the broadest audience of buyers before it officially goes active. Real-time signals such as saves, shares and tour requests help sellers and their agents refine their strategy before the listing hits the market. Highlight the right features. Outdoor amenities, personalized or custom features, and recent renovations contribute to higher sale prices, so sellers should flaunt them in their listings. Homes with outdoor kitchens, quartzite countertops or white oak floors sell for as much as 5.3% more. Win the scroll. Today's buyers fall in love online before they ever set foot in a home. Listings with high-resolution photography, virtual tours and interactive floor plans, which are all included in Zillow Showcase℠, tend to sell faster and for more money. Methodology
This research was conducted by Zillow's behavioral science team, which surveyed more than 4,400 recent and prospective home buyers around the country. In the study, buyers were randomly assigned images of a home with interior spaces painted in one of 11 colors. Each color got a score based on how much buyers liked a home, how interested they were in buying the home, their likelihood of touring the home and the price they would be willing to pay for the home.
About Zillow Group
Zillow Group, Inc. (Nasdaq: Z and ZG) is reimagining real estate to make home a reality for more and more people.
As the most visited real estate app and website in the United States, Zillow connects hundreds of millions of consumers with innovative technology, trusted agents and loan officers, and seamless digital solutions. With industry-leading tools and resources, Zillow supercharges real estate professionals so hey can grow their businesses and deliver exceptional client experiences. For renters and housing providers, Zillow offers not only a robust marketplace but a set of end-to-end products and services to streamline applications, leases, payments and more.
Zillow's ecosystem spans the entire home journey — from dreaming and shopping to renting, buying, selling and financing.
Zillow Group's affiliates, subsidiaries and brands include Zillow®, Zillow Premier Agent®, Zillow Home Loans®, Zillow Rentals®, Zillow® New Construction, Trulia®, StreetEasy®, Out East®, HotPads®, Follow Up Boss®, ShowingTime®, dotloop® and Zillow® Closing.
New York, New York--(Newsfile Corp. - June 16, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Zillow Group, Inc. (NASDAQ: Z) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zillow securities between February 11, 2025 and May 7, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/Z.
Zillow Case Details
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that:
Zillow's agreement with Redfin Corporation was not a "partnership," but rather an acquisition of Redfin's business; as a result of the Redfin Agreement, Zillow faced a materially heightened risk of regulatory scrutiny and liability under federal antitrust laws; upon the filing of an antitrust lawsuit, Zillow continued to downplay its legal exposure; and as a result, defendants' statements about Zillow's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.What's Next for Zillow Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/Z, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Zillow you have until August 10, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Zillow Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Zillow Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising.
Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301082
Source: Bronstein, Gewirtz & Grossman, LLC
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
New York, New York--(Newsfile Corp. - June 16, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of Class A or Class C common stock of Zillow Group, Inc. (NASDAQ: ZG) (NASDAQ: Z) between February 11, 2025 and May 7, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 10, 2026 in the securities class action first filed by the Firm.
SO WHAT: If you purchased Zillow common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Zillow class action, go to https://rosenlegal.com/cases/zillow-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 10, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Zillow's agreement with Redfin Corporation was not a "partnership," but rather an acquisition of Redfin's business; (2) as a result of the Redfin Agreement, Zillow faced a materially heightened risk of regulatory scrutiny and liability under federal antitrust laws; (3) upon the filing of an antitrust lawsuit, Zillow continued to downplay its legal exposure; and (4) as a result, defendants' statements about Zillow's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Zillow class action, go to https://rosenlegal.com/cases/zillow-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301728
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming August 10, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Zillow Group, Inc. (“Zillow” or the “Company”) (NASDAQ: Z, ZG) Class A or Class C common stock between February 11, 2025 and May 7, 2026, inclusive (the “Class Period”).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ZILLOW GROUP, INC. (Z, ZG), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PA.
A securities fraud class action lawsuit has been filed on behalf of Zillow investors after its stock plummeted over 16% because of Zillow’s alleged anticompetitive agreement with Redfin, potentially violating federal securities laws.
NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Zillow Group, Inc. (NASDAQ:Z, ZG) and certain of the Company’s senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws.
A securities fraud class action lawsuit has been filed on behalf of Zillow investors after its stock plummeted over 16% because of Zillow’s alleged anticompetitive agreement with Redfin, potentially violating federal securities laws.
ShareIf you invested in Zillow, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/zillow-class-action-lawsuit.
Key Details of the Zillow ($Z, $ZG) Class Action:
Lead Plaintiff Deadline: August 10, 2026Alleged Misconduct: Securities fraud relating to Zillow’s allegedly anticompetitive agreement with Redfin CorporationLargest Alleged Stock Drop: February 11, 2026 – 16.54% Stock Drop on Class C shares; 17.13% Stock Drop on Class A shares.Court: U.S. District Court for the Western District of WashingtonAction: Contact BFA Law to discuss your rightsInvestors have until August 10, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Zillow Class C and Class A common stock. The class action is pending in the U.S. District Court for the Western District of Washington. It is captioned Breidert v. Zillow Group, Inc., et al., No. 26-cv-02016.
Why is Zillow Being Sued for Securities Fraud?
On February 6, 2025, Zillow entered into an agreement with Redfin through which Zillow became the exclusive provider of multifamily rental listings on Redfin’s platform and affiliate websites, including Rent.com. According to the complaint, during the relevant period, Zillow characterized the agreement with Redfin as a “partnership” that would provide Zillow exclusive access to Redfin’s advertising platform.
As alleged, in truth, under the terms of the agreement, Zillow paid Redfin $100 million to stop competing with Zillow, facilitate the transition of its multifamily rental advertising business to Zillow, and close the remainder of its business.
Why did Zillow’s Stock Drop?
On September 30, 2025, the FTC filed a complaint against Zillow and Redfin alleging violations of the federal antitrust laws. According to the FTC complaint, “Zillow and Redfin executed an unlawful agreement to remove competition from [the online rental marketplaces industry], starting with a $100 million payment to Redfin to exit the [Internet Listing Services] market.” In sum, the FTC alleged, “[t]his agreement is nothing more than an end run around competition on the merits with Redfin for customers…” This news caused the price of Zillow’s Class C and A common stock to decline 4.33% and 4.5%, respectively.
On February 10, 2026, Zillow’s CFO told investors that Zillow experienced increased legal expenses which “will result in approximately 200 basis points headwind to EBITDA margins in Q1.” On this news, the price of Zillow’s Class C and A common stock declined 16.54%, and 17.13%, respectively.
Finally, on May 7, 2026, Reuters reported that a “federal judge rejected [Zillow and Redfin’s] request to end a [FTC] lawsuit accusing them of illegally agreeing to suppress competition for online apartment rental listings.” This news caused the price of Zillow’s Class C and A common stock to decline 1.9% and 1.76%, respectively.
Click here for more information: https://www.bfalaw.com/cases/zillow-class-action-lawsuit.
What Can You Do?
If you invested in Zillow, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 16, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until August 10, 2026 to file lead plaintiff applications in a securities class action lawsuit against Zillow Group, Inc. (NASDAQ: ZG) (NASDAQ: Z) ("Zillow" or the "Company"), if they purchased or otherwise acquired Zillow Class A or Class C common stock between February 11, 2025 and May 7, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Western District of Washington.
Cannot view this video? Visit:
https://www.youtube.com/watch?v=hIyQUNEoCGc
What You May Do
If you purchased shares of Zillow as described above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-zg-z/?prs=nf to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by August 10, 2026.
CLICK HERE for more information
About the Lawsuit
Zillow and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) Zillow's agreement with Redfin was not a "partnership," but rather an acquisition of Redfin's business; (ii) as a result of the Redfin Agreement, Zillow faced a materially heightened risk of regulatory scrutiny and liability under federal antitrust laws; (iii) upon the filing of an antitrust lawsuit, Zillow continued to downplay its legal exposure; and (iv) as a result, Defendants' statements about Zillow's business, operations, and prospects, were materially false and misleading and or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
The case is Breidert v. Zillow Group, Inc., et al., 26-cv-02016.
To Learn More, Click HERE
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors, in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Zillow (Z) To Contact Him Directly To Discuss Their Options
If you purchased or acquired Zillow Class A or Class C common stock between February 11, 2025 and May 7, 2026 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) --
What’s Happening:
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Zillow Group, Inc. (“Zillow” or the “Company”) (NASDAQ:Z) in the United States District Court for the Western District of Washington on behalf of all persons and entities who purchased or otherwise acquired Zillow Class A or Class C common stock between February 11, 2025 and May 7, 2026, both dates inclusive (the “Class Period”). Investors have until August 10, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Allegation Details:
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Zillow's agreement with Redfin Corporation was not a "partnership," but rather an acquisition of Redfin's business; (2) as a result of the Redfin Agreement, Zillow faced a materially heightened risk of regulatory scrutiny and liability under federal antitrust laws; (3) upon the filing of an antitrust lawsuit, Zillow continued to downplay its legal exposure; and (4) as a result, defendants' statements about Zillow's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. Next Steps:
If you purchased or otherwise acquired Zillow shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
Walmart (NYSE:WMT | WMT Price Prediction) is the comfort trade of 2026, hitting fresh highs on the back of a 29% one-year gain and a reputation as the retailer that always finds a way. But here’s what you should actually be watching.
The Hot Ticker Is Quietly Breaking Walmart now trades at a trailing PE of 43 and a forward PE of 41, which is what investors used to pay for hyper-growth software. What are they getting for it? Quarterly revenue growth of 7.3% YoY, a net profit margin of 3.14%, and a dividend yield of 0.79%. The most recent quarter barely cleared the bar: revenue of $175.68B grew 6.1% YoY while adjusted EPS of $0.66 narrowly beat expectations, both rounding errors.
The real tell is underneath the headline. Free cash flow turned negative at $1.9 billion as capex surged 34% YoY to $6.68 billion. Operating cash flow fell 12.4% YoY. Return on investment slipped 40 basis points to 14.9%. And management is still flagging IEEPA tariff uncertainty as an unresolved risk. This is a mature retailer paying a growth multiple while its cash generation goes the wrong way. The PEG ratio sums it up: 4.77.
The Better Buy Is Growing Ten Times Faster MercadoLibre (NASDAQ:MELI) is the Latin American e-commerce and fintech operator the headline-chasers are ignoring, and that is exactly the setup retirement money should want. Three reasons it belongs in the portfolio Walmart is crowding out.
1. Growth velocity that is not slowing. Q1 2026 revenue hit $8.85 billion, up 49.03% YoY, the company’s strongest growth rate since Q2 2022. Commerce grew 47% YoY; fintech grew 51% YoY. Brazil revenue grew 55% YoY in USD, Mexico 62%. Operating cash flow more than doubled to $2.08 billion, +119.81% YoY.
2. A fintech engine built for inflation. Mercado Pago’s monthly active users hit 83 million, +29% YoY, with AUM near $20 billion, +77% YoY. The credit portfolio grew 104% YoY to $6.6 billion with 2.7 million cards issued in the quarter. With over half of Mexico’s population using informal credit and Argentina credit-to-GDP at one-fifth of Brazil’s level, this is structural penetration with a long runway.
3. Valuation and insider conviction line up. MELI’s PEG ratio is 0.98 against a forward PE of 31. Director Alejandro Aguzin spent open-market dollars on 600 shares at roughly $1,655 on May 22, 2026, the kind of deliberate accumulation boards rarely do at tops. Analyst consensus sits at $2,216.96 against today’s $1,646.36, with the stock down 30.59% over the past year. That is the discount.
The Action Walmart at 43 times earnings with shrinking cash flow is a crowded defensive trade dressed up as a growth story. MercadoLibre at 42 times trailing earnings is growing ten times faster, compounding a fintech book at triple digits, and trading well below its 52-week high of $2,645.22. For retirement investors weighing the two, the data points to a wide valuation and growth gap, with MELI trading at a discount to consensus while WMT trades at a growth multiple on decelerating cash flow.
In the latest close session, MercadoLibre (MELI - Free Report) was up +1.68% at $1,674.08. The stock exceeded the S&P 500, which registered a loss of 0.57% for the day. Meanwhile, the Dow experienced a rise of 0.64%, and the technology-dominated Nasdaq saw a decrease of 1.15%.
The operator of an online marketplace and payments system in Latin America's stock has climbed by 3.81% in the past month, exceeding the Retail-Wholesale sector's loss of 3.04% and the S&P 500's gain of 2.14%.
Analysts and investors alike will be keeping a close eye on the performance of MercadoLibre in its upcoming earnings disclosure. On that day, MercadoLibre is projected to report earnings of $8.69 per share, which would represent a year-over-year decline of 15.71%. At the same time, our most recent consensus estimate is projecting a revenue of $9.77 billion, reflecting a 43.9% rise from the equivalent quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $40.97 per share and a revenue of $40.36 billion, indicating changes of +3.98% and +39.68%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for MercadoLibre. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. As of now, MercadoLibre holds a Zacks Rank of #5 (Strong Sell).
In terms of valuation, MercadoLibre is presently being traded at a Forward P/E ratio of 40.19. This represents a premium compared to its industry average Forward P/E of 16.73.
We can additionally observe that MELI currently boasts a PEG ratio of 1.01. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Internet - Commerce was holding an average PEG ratio of 1.01 at yesterday's closing price.
The Internet - Commerce industry is part of the Retail-Wholesale sector. Currently, this industry holds a Zacks Industry Rank of 109, positioning it in the top 45% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
The company's revolutionary, patented bipolar electrode-to-pack technology increases the battery energy and power densities; reducing weight, volume, and cost
, /PRNewswire/ -- Solidion Technology, Inc. (Nasdaq: STI), an advanced battery technology solutions provider, today unveiled their patented bipolar electrode-to-pack (BEEP) battery technology, engineered to power electric vertical take-off and landing (eVTOL) aircraft, drones, robots, AI data centers, space infrastructure and devices.
Conventional Monopolar Battery vs Bipolar Battery Architecture Rather than making individual cells and modules, Solidion's AI-assisted designed BEEP technology entails directly stacking and connecting bipolar electrodes and solid electrolyte layers in series and in parallel to produce a solid-state battery pack that delivers exceptional power and energy densities.
Solid-state batteries are expected to revolutionize the electric vehicle and space industries with their inherent safety, fast charging, significantly extended driving or flying range on a single battery charge. However, two major issues have prevented the wide-spread commercialization of solid-state lithium batteries:
the difficulty and high cost of manufacturing solid-state batteries and the limited space and payload weight available in an EV for ground, sea, air, or space transportation to accommodate a bulky and heavy battery system. Current battery pack designs devote much of that space to fire mitigation, a large number of connectors between cells or modules, and large volumes of protective housing materials. Solidion's BEEP technology solves both this design issue and reduces the manufacturing challenges, while contributing to reduced battery weight, volume and cost. This is accomplished owing to the BEEP pack requiring only one casing and a small number of connectors – instead of the hundreds of housings and connectors in today's batteries. The bipolar electrode stacking procedure is intrinsically simpler and easier when compared to making individual cells and using external cables to connect multiple pre-fabricated cells.
Jaymes Winters, Chief Executive Officer of Solidion Technology, stated:
"BEEP represents a fundamental rethinking of how battery packs are built. By eliminating the redundant housings, connectors, and fire mitigation systems that burden conventional designs, we've created a pathway to batteries that are lighter, smaller, safer, and less expensive to manufacture — precisely the attributes demanded by next-generation eVTOL, space, and AI infrastructure applications. We believe this technology positions Solidion at the forefront of the solid-state battery revolution."
About Solidion Technology, Inc.
Headquartered in Dallas, Texas, with pilot production facilities in Dayton, Ohio, Solidion Technology (NASDAQ: STI) is an advanced battery technology solutions provider focused on manufacturing next-generation battery materials and components, and developing high-performance batteries for energy storage, including UPS systems serving the AI data center market, electric vehicles, and aerospace applications. The Company holds a portfolio of over 385 patents, covering innovations such as high-capacity, silane-gas-free and graphene-enabled silicon anodes, biomass-based graphite, and advanced lithium-sulfur and lithium-metal technologies.
For more information, please visit www.solidiontech.com or contact Investor Relations.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Solidion Technology Inc. (NASDAQ: STI) (the "Company," "Solidion," "we," "our" or "us") desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words "forecasts," "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "expect," and similar expressions, as they relate to us, are intended to identify forward-looking statements. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as may be required by law.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?
Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Sea Limited Sponsored ADR (SE - Free Report) .
Sea Limited currently has an average brokerage recommendation (ABR) of 1.38, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 20 brokerage firms. An ABR of 1.38 approximates between Strong Buy and Buy.
Of the 20 recommendations that derive the current ABR, 15 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 75% and 10% of all recommendations.
Brokerage Recommendation Trends for SE
Check price target & stock forecast for Sea Limited here>>>
The ABR suggests buying Sea Limited, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.
This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
ABR Should Not Be Confused With Zacks RankIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
Is SE a Good Investment?Looking at the earnings estimate revisions for Sea Limited, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $4.24.
Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Sea Limited. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Sea Limited.
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.
Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.
One company to watch right now is Occidental Petroleum (OXY - Free Report) . OXY is currently sporting a Zacks Rank #2 (Buy), as well as an A grade for Value.
Another valuation metric that we should highlight is OXY's P/B ratio of 1.63. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. This company's current P/B looks solid when compared to its industry's average P/B of 1.70. OXY's P/B has been as high as 1.94 and as low as 1.27, with a median of 1.65, over the past year.
Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. Some people prefer this metric because sales are harder to manipulate on an income statement. This means it could be a truer performance indicator. OXY has a P/S ratio of 2.29. This compares to its industry's average P/S of 2.84.
Finally, we should also recognize that OXY has a P/CF ratio of 4.59. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. OXY's P/CF compares to its industry's average P/CF of 5.27. Over the past 52 weeks, OXY's P/CF has been as high as 4.78 and as low as 3.32, with a median of 4.31.
Value investors will likely look at more than just these metrics, but the above data helps show that Occidental Petroleum is likely undervalued currently. And when considering the strength of its earnings outlook, OXY sticks out as one of the market's strongest value stocks.
Intellia Therapeutics (NTLA 2.48%), a clinical-stage biotech company, did not start the year on a strong note. The company was dealing with regulatory issues: The U.S. Food and Drug Administration had put a pair of its phase 3 studies on clinical hold following the death of a patient from liver damage. However, Intellia Therapeutics was able to overcome that obstacle and resume its late-stage clinical trials. And since then, the company has made even more progress on the clinical front, helping send its stock price much higher. Shares are up 58% year to date. Is it still time to invest in Intellia Therapeutics?
Image source: Getty Images.
A promising gene editing treatment On April 27, Intellia Therapeutics announced positive results from a phase 3 clinical trial for one of its leading candidates, lonvo-z. This investigational gene-editing medicine targets hereditary angioedema (HAE), a rare genetic condition that causes painful swelling attacks across the body. Although there are standards of care for this condition, there is no permanent cure. The disease, although very rare (it affects about one person in 50,000), places a significant financial burden on patients, their families, and the healthcare system.
Lonvo-z could help address some of those issues as a one-time gene editing treatment for HAE. But is it effective? The phase 3 data Intellia Therapeutics recently released tells us that it is. In the study, patients who received a single infusion of lonvo-z had an 87% reduction in attacks compared with those who received a placebo after about six months of treatment. Further, 62% of patients who received lonvo-z were completely free of attacks, compared with just 11% in the placebo group.
Intellia Therapeutics has begun submitting an application to the FDA for approval of lonvo-z. It plans to launch the medicine in the first half of 2027.
Looking at the commercial opportunity Lonvo-z could become the standard of care in HAE. How much in sales might the medicine generate at its peak? First, note that since it affects one person in 50,000, that means there are roughly 7,000 people in the U.S. who suffer from it. That seems like a small patient population. However, gene editing treatments tend to be expensive. We don't know how much lonvo-z will cost if it earns approval, but it wouldn't be surprising if it goes for several hundred thousand dollars, perhaps even over $1 million. It's also worth noting that lonvo-z is an in vivo gene editing therapy.
Today's Change
(
-2.48
%) $
-0.37
Current Price
$
14.55
That means it avoids the complex cell collection and editing process that ex vivo methods typically require and that can take weeks to complete. In fact, lonvo-z is administered in just two to four hours, after which the patient can go home. This will make the medicine much more attractive to health insurance companies and other third-party payers, as well as to patients and their families. For the sake of argument, let's suppose lonvo-z will be priced at $1 million per treatment course, while keeping in mind that, since this is a one-time gene-editing treatment, once a patient receives the therapy, they are no longer in the addressable pool.
So, it could have a total addressable opportunity of $7 billion in the U.S. It likely won't capture this entire opportunity on its own. Assuming a 50% penetration rate, we could estimate lonvo-z's lifetime sales at about $3.5 billion in the country. And since it will take a while to ramp up revenue for the medicine, annual peak sales may never get to $1 billion.
Is Intellia Therapeutics stock a buy? The market is well aware that even though lonvo-z looks promising, its commercial opportunity in HAE is fairly small. That's why even after its impressive run this year, Intellia Therapeutics is worth just about $2.1 billion. In my view, that's a somewhat fair valuation given lonvo-z's potential. However, Intellia Therapeutics has other pipeline candidates that could be even more promising. Nex-z, the medicine whose phase 3 studies were put on clinical hold by the FDA, is being investigated in patients with transthyretin amyloidosis (ATTR).
This progressive genetic condition leads to various cardiovascular (and other) symptoms and can be life-threatening. Intellia Therapeutics is developing nex-z in partnership with Regeneron Pharmaceuticals (REGN 0.04%). There are between 250,000 and 500,000 patients with ATTR worldwide, and there is a significant need for new treatment options. Provided nex-z can ace its ongoing late-stage clinical trials, Intellia Therapeutic' prospects will get much brighter, and its shares will soar. We likely won't see results for nex-z's ongoing studies until next year, though, given that Intellia Therapeutics plans to complete enrollment for one of the studies in the second half of 2026.
Intellia Therapeutics has enough cash on hand to keep the lights on through all this, though, at least until 2028, according to management. And the collaboration with a biotech giant of Regeneron's stature can help in that department as well. With all that said, what should investors do? There is a significant risk in investing in a clinical-stage company, particularly one specializing in gene editing. Unforeseen clinical and regulatory setbacks are fairly common in this niche. And if that does happen to Intellia, its share price will drop off a cliff. However, for investors comfortable with significant volatility, Intellia Therapeutics might offer ample upside if it can execute its strategy nearly flawlessly over the next few years.
SpaceX (NASDAQ:SPCX) spent more than two decades transforming itself from an ambitious rocket startup into one of the world’s most important technology companies. Today, it dominates commercial space launches, operates the largest satellite internet network through Starlink, and has expanded into markets that span telecommunications, defense, aerospace, and space exploration.
Led by Elon Musk, the company sits at the center of several industries measured in the trillions of dollars, giving investors a rare opportunity to buy a business with multiple long-term growth drivers under one roof.
That combination of market leadership and future potential helps explain why SpaceX’s public debut captured so much attention. The company held the largest IPO in history last Friday, raising $75 billion and entering the market with a valuation of $1.8 trillion. Investors wasted little time bidding shares higher, and the rally has quickly propelled SpaceX up the ranks of the world’s most valuable companies.
SpaceX Is Already Climbing the Market-Cap Rankings SpaceX raised $75 billion in its IPO last Friday and entered the public markets with a valuation of approximately $1.8 trillion. That immediately made SPCX the world’s eighth-largest publicly traded company. But the market wasn’t finished buying.
While the space company closed its first trading day 19% higher, lifting its market capitalization to roughly $2.1 trillion, Monday brought another wave of buying. The stock gained 19.6% more, adding approximately $412 billion in market value in a single session and pushing its valuation to $2.52 trillion.
That move allowed SpaceX to pass Taiwan Semiconductor Manufacturing (NYSE:TSM | TSM Price Prediction) and claim the No. 7 spot among the world’s most valuable companies.
Here’s how the leaderboard currently looks:
Rank Company Market Value 1. Nvidia (NASDAQ:NVDA) $5.14 trillion 2. Alphabet (NASDAQ:GOOG) $4.47 trillion 3. Alphabet (NASDAQ:GOOGL) $4.47 trillion 4 Apple (NASDAQ:AAPL) $4.35 trillion 5 Microsoft (NASDAQ:MSFT) $2.97 trillion 6 Amazon (NASDAQ:AMZN) $2.65 trillion 7 SpaceX $2.52 trillion 8 Taiwan Semiconductor Manufacturing $2.29 trillion The next target is obvious. Amazon’s $2.65 trillion valuation sits only about 5.2% above SpaceX’s current value.
Amazon Is Within Reach, Microsoft Is Possible. At its current pace, overtaking Amazon should be easy as it would not require much additional appreciation. A gain of roughly 5.2% would be enough to move SpaceX into sixth place. Microsoft presents a slightly larger hurdle, but not an impossible one. With a market capitalization of $2.97 trillion, Microsoft stands about 18% above SpaceX’s current valuation.
That is still within the realm of possibility during the early stages of a hot IPO. It could reach it by week’s end if the momentum continues. The challenge grows much steeper after that.
Apple, currently the fourth-largest company, carries a market capitalization of $4.35 trillion. That is approximately 72% larger than SpaceX’s current value. For a company already worth more than $2.5 trillion, adding nearly $2 trillion in market value is no small task.
IPO Euphoria Doesn’t Last Forever History offers an important lesson for investors. Mega-IPOs often experience a period of enthusiasm immediately after listing as institutions, retail investors, and momentum traders compete for shares.
That said, the initial excitement rarely lasts indefinitely. Many high-profile IPOs spend months — or even years — working through lofty expectations after the first burst of enthusiasm fades. The larger the company, the harder it becomes to sustain rapid gains because each percentage increase represents hundreds of billions of dollars in additional value.
SpaceX remains a unique business. It dominates commercial launches, has a growing satellite business, and benefits from the leadership of Elon Musk. Its long-term growth prospects appear substantial.
Granted, a great company is not automatically a great investment at every price. Valuation still matters. Investors who buy solely because a stock is rising often discover that momentum can reverse just as quickly, particularly with IPOs.
Key Takeaway In short, SpaceX’s debut has been extraordinary. A $75 billion IPO, a rise from $1.8 trillion to $2.52 trillion in two trading sessions, and already placing seventhmfst among the world’s most valuable companies is a remarkable achievement.
Amazon sits only 5.2% away, and Microsoft is within 18%. Apple, however, remains in another league altogether.
Regardless of where SpaceX ranks next week, investors should focus on a more important question: Would they be comfortable owning the company for the next decade? Successful investing is rarely about making a quick buck. It is about buying exceptional businesses, holding them through market cycles, and allowing compounding to do the heavy lifting over years and decades.
SpaceX may ultimately reward patient shareholders. Chasing hype, however, has a much less reliable track record.
TSMC (TSM - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this chip company have returned +11.5% over the past month versus the Zacks S&P 500 composite's +2.1% change. The Zacks Semiconductor - Circuit Foundry industry, to which TSMC belongs, has gained 9.2% over this period. Now the key question is: Where could the stock be headed in the near term?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
For the current quarter, TSMC is expected to post earnings of $3.69 per share, indicating a change of +49.4% from the year-ago quarter. The Zacks Consensus Estimate has changed +0.9% over the last 30 days.
The consensus earnings estimate of $15.3 for the current fiscal year indicates a year-over-year change of +43.7%. This estimate has changed +0.3% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $19.07 indicates a change of +24.7% from what TSMC is expected to report a year ago. Over the past month, the estimate has changed +0.4%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for TSMC.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue GrowthWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
For TSMC, the consensus sales estimate for the current quarter of $39.76 billion indicates a year-over-year change of +32.2%. For the current and next fiscal years, $161.88 billion and $204.92 billion estimates indicate +32.2% and +26.6% changes, respectively.
Last Reported Results and Surprise HistoryTSMC reported revenues of $35.9 billion in the last reported quarter, representing a year-over-year change of +40.6%. EPS of $3.49 for the same period compares with $2.12 a year ago.
Compared to the Zacks Consensus Estimate of $35.5 billion, the reported revenues represent a surprise of +1.13%. The EPS surprise was +5.44%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
TSMC is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about TSMC. However, its Zacks Rank #2 does suggest that it may outperform the broader market in the near term.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about TSMC (TSM - Free Report) .
TSMC currently has an average brokerage recommendation (ABR) of 1.35, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 17 brokerage firms. An ABR of 1.35 approximates between Strong Buy and Buy.
Of the 17 recommendations that derive the current ABR, 13 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 76.5% and 11.8% of all recommendations.
Brokerage Recommendation Trends for TSM
Check price target & stock forecast for TSMC here>>>
The ABR suggests buying TSMC, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.
In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.
With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.
Zacks Rank Should Not Be Confused With ABRIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
Should You Invest in TSM?In terms of earnings estimate revisions for TSMC, the Zacks Consensus Estimate for the current year has increased 0.3% over the past month to $15.3.
Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for TSMC. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, the Buy-equivalent ABR for TSMC may serve as a useful guide for investors.
Supply chain bottlenecks and margin pressures are two key headwinds Ali Mogharabi sees for Apple (AAPL) that can hit what he considers strong demand for its products. A memory shortage making tech products more expensive adds to those uncertainties, though Ali believes Apple can pass rising costs onto the consumer.
In the latest close session, TSMC (TSM - Free Report) was down 3.53% at $425.83. This change lagged the S&P 500's daily loss of 0.57%. Elsewhere, the Dow gained 0.64%, while the tech-heavy Nasdaq lost 1.15%.
The chip company's stock has climbed by 11.48% in the past month, exceeding the Computer and Technology sector's gain of 2.85% and the S&P 500's gain of 2.14%.
Investors will be eagerly watching for the performance of TSMC in its upcoming earnings disclosure. The company's upcoming EPS is projected at $3.69, signifying a 49.39% increase compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $39.76 billion, indicating a 32.23% increase compared to the same quarter of the previous year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $15.3 per share and revenue of $161.88 billion. These totals would mark changes of +43.66% and +32.22%, respectively, from last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for TSMC. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.32% higher within the past month. TSMC presently features a Zacks Rank of #2 (Buy).
With respect to valuation, TSMC is currently being traded at a Forward P/E ratio of 28.86. This represents no noticeable deviation compared to its industry average Forward P/E of 28.86.
It's also important to note that TSM currently trades at a PEG ratio of 1.29. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. TSM's industry had an average PEG ratio of 1.29 as of yesterday's close.
The Semiconductor - Circuit Foundry industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 6, which puts it in the top 3% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Key Takeaways Abbott's CGM sales rose 7.5% to $2 billion in Q1, impacted by tender renewal delays and tough comparisons.ABT expects CGM to return to double-digit growth in Q2, supported by market trends and innovation.Abbott expanded Libre with dual glucose-ketone sensors, AI features and broader Lingo app access. Abbott’s (ABT - Free Report) continuous glucose monitoring (CGM) business is a key driver within its Diabetes Care division, although the pace moderated in the first quarter of 2026. Sales rose 7.5% to $2 billion, reflecting a delay in the renewal process tied to an international tender, as well as a difficult comparison to the prior year related to the shelf restocking dynamics. On a promising note, management expects CGM to return to double-digit growth in the second quarter.
The Libre portfolio, Abbott’s flagship CGM franchise, is used by more than 8 million people across more than 60 countries. Looking at the broader trend, the business added more than $1 billion in sales in 2025 for the third consecutive year. Abbott pins its success in CGM to favorable underlying market fundamentals, cost and scale advantages and continued innovation, which have supported adoption across all of the various user groups.
More recently, the company broadened the portfolio with CE Mark approval for Libre Duo and Libre Duo 10 Day, described as the world's first dual glucose???ketone sensing technology for people with diabetes. The systems provide real-time visibility into glucose levels for daily diabetes management as well as rising ketones associated with diabetic ketoacidosis (DKA). Shortly afterward, Medtronic’s Diabetes carve-out, MiniMed, expanded its agreement with Abbott to commercialize these dual glucose-ketone sensors for exclusive integration with MiniMed smart dosing systems.
Another landmark study conducted across 24 U.K. clinical sites and involving 303 participants found that people using FreeStyle Libre CGM achieved better glucose outcomes than those relying on traditional fingersticks.
Earlier this year, Abbott introduced Libre Assist, a generative AI-powered feature within the Libre app that helps users predict how food choices affect their glucose levels and provides personalized meal guidance. In late 2025, Abbott also expanded its over-the-counter CGM and app, Lingo, to Android devices, extending access to real-time glucose data to more people.
Updates From ABT’s Industry PeersDexCom (DXCM - Free Report) recently announced results from the CONNECT randomized controlled trial, demonstrating clinically significant benefit for all adult Type 2 non-insulin using patients regardless of age, gender, ethnicity, baseline A1C, body mass index, education level, income and insurance coverage. It also showed an additional clinically significant reduction in A1C when using Dexcom G7 with various combinations of current standards of care diabetes medication, including metformin, GLP-1s and SGLT2s.
Insulet (PODD - Free Report) announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. Results from the STRIVE pivotal trial and the EVOLUTION 3 feasibility study showed meaningful improvements in glucose control for people with diabetes using Insulet’s future AID system — Omnipod 6 — and fully closed-loop system for type 2 diabetes.
The Zacks Rundown for ABT StockOver the past three months, ABT shares have plunged 19.9% compared with the industry’s 14.4% decline.
Image Source: Zacks Investment Research
Abbott is trading at a forward, five-year Price/Sales (P/S) of 2.94X, lower than its median, but above the industry average.
Image Source: Zacks Investment Research
Here’s how estimates for Abbott’s 2026 and 2027 earnings are shaping up.
Image Source: Zacks Investment Research
Abbott currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Choosing between the State Street Health Care Select Sector SPDR ETF (XLV +0.03%) and the iShares U.S. Healthcare ETF (IYH 0.08%) often comes down to a preference for lower fees versus broader diversification.
Both funds provide concentrated exposure to the U.S. healthcare market, encompassing pharmaceutical giants and medical technology companies. While they share top holdings like Eli Lilly and Co. (LLY 0.62%), Johnson & Johnson (JNJ 0.18%), and AbbVie Inc. (ABBV +0.47%), differences in cost and market-cap concentration could significantly impact long-term results.
Snapshot (cost & size)MetricIYHXLVIssueriSharesSPDRExpense ratio0.38%0.08%1-yr return (as of June 8, 2026)15.30%15.60%Dividend yield1.20%1.70%Beta0.580.57AUM$3.2 billion$39.2 billionBeta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
The State Street Health Care Select Sector SPDR ETF is notably more affordable, with an expense ratio of 0.08% compared to the 0.38% charged by the iShares U.S. Healthcare ETF. For income-focused investors, XLV also offers a higher payout, providing more yield per dollar invested than IYH.
Performance & risk comparisonMetricIYHXLVMax drawdown (5 yr)(17.90%)(17.10%)Growth of $1,000 over 5 years (total return)$1,273$1,342What's insideThe State Street Health Care Select Sector SPDR ETF (XLV) provides exposure to 60 healthcare companies specifically selected from the S&P 500. Its largest positions include Eli Lilly and Co. at 16.52%, Johnson & Johnson at 10.15%, and AbbVie Inc. at 7.15%. Launched in 1998, it has paid $2.51 per share over the trailing 12 months. Its portfolio is 100% weighted toward the healthcare sector and excludes smaller companies not found in the large-cap benchmark.
The iShares U.S. Healthcare ETF (IYH) holds a larger basket of 102 stocks, which may appeal to those seeking exposure to mid-cap companies alongside large-cap leaders. Its largest positions include Eli Lilly and Co. at 16.17%, Johnson & Johnson at 9.81%, and AbbVie Inc. at 6.94%. Launched in 2000, it has a trailing-12-month dividend of $0.81 per share. Like its counterpart, it maintains 100% exposure to the healthcare sector but offers slightly broader diversification across market capitalizations.
For more guidance on ETF investing, check out the full guide at this link.
Which looks like the better buyThe State Street Health Care Select Sector SPDR ETF (XLV) and the iShares U.S. Healthcare ETF (IYH) are both viable choices for those who are seeking exposure to the U.S. healthcare sector. Let’s see how these exchange-traded funds (ETFs) compare to one another.
First, there’s XLV. This fund has a history stretching back nearly 30 years, to 1998, making it one of the first sector-focused ETFs. Over its long history, the fund has performed well. Its 812% return over its lifetime equates to a compound annual growth rate (CAGR) of 8.4%. The benchmark S&P 500, by comparison, has generated a total return of 907% and a CAGR of 8.8% over this same period. In other words, the XLV has slightly underperformed the market over its lifetime — but not by much. In addition, there were long stretches during which XLV outperformed.
At any rate, XLV offers investors wide exposure to the healthcare sector at an affordable price; the fund’s expense ratio is only 0.08%. As for income, the fund has a respectable dividend yield of 1.6%.
Turning to IYH, this fund has a similarly long history, having been started in 2000. Over its lifetime, the fund has generated a total return of 596%, equating to a CAGR of 7.7%. However, the S&P 500 has delivered better returns, with a 728% total return and an 8.5% CAGR over the same period.
As for fees, IYH has higher fees compared to XLV, with an expense ratio of 0.38%. Its dividend yield, meanwhile, is lower at 1.3%.
In summary, many investors, particularly buy-and-hold investors, may favor XLV due to its lower fees, higher dividend yield, and superior historical performance.
Analysts project that the weight loss market will grow rapidly in the coming years. Investors looking to cash in on this may turn to the companies that lead this niche: Eli Lilly (LLY 0.62%) and Novo Nordisk (NVO 0.73%). These pharmaceutical giants have moved in opposite directions on the market over the past year: Eli Lilly has gained 40%, while Novo Nordisk's shares have dropped 42%. But that doesn't tell us which is more likely to perform well over the medium term. Let's decide that by looking more deeply into each company.
Image source: The Motley Fool.
The market leader Eli Lilly's weight loss lineup includes Zepbound, which is currently the best-selling medicine in this niche. The company also recently received approval for Foundayo. This oral GLP-1 therapy is helping it expand its addressable market and attract patients who were hesitant to use injectable drugs. Eli Lilly is posting outstanding revenue and earnings growth, partly thanks to its dominance in chronic weight management. In the first quarter, the company's revenue jumped 56% year over year to $19.8 billion. Its earnings per share soared 170% year over year to $8.26.
Today's Change
(
-0.62
%) $
-7.05
Current Price
$
1122.30
In addition to its current crop of medicines, Eli Lilly has a deep pipeline in weight management. One of the more promising candidates it is working on is called retatrutide, an investigational therapy that mimics the action of three gut hormones, which could lead to improved efficacy. Retatrutide has performed extremely well in clinical studies so far. Meanwhile, beyond its weight-loss lineup and pipeline, Eli Lilly has important products and candidates in other fields, including oncology, immunology, and neuroscience. So, Eli Lilly isn't just a weight loss stock.
Can Novo Nordisk keep up? Novo Nordisk was once the leader in the anti-obesity market. Now, the company is playing catch-up. However, several recent developments could help the Denmark-based drugmaker avoid being left in the dust by its competitor. Novo Nordisk launched its oral GLP-1, Wegovy pill, in January, months before Foundayo earned approval. Oral Wegovy has been a smashing success so far, with more than two million prescriptions as of the end of the first quarter. Meanwhile, the original injectable Wegovy continues to post decent sales growth, too.
Today's Change
(
-0.73
%) $
-0.32
Current Price
$
43.60
Further, Novo Nordisk has earned approval for a high-dose formulation of Wegovy that is even more effective. This could help the company compete with Zepbound. Novo Nordisk also has attractive pipeline candidates, including its own triple agonist, UBT251. The company's amycretin, a dual agonist of the GLP-1 and amylin hormones, is also undergoing phase 3 studies in oral and subcutaneous formulations, while the company's CagriSema is expected to earn approval by year-end.
Novo Nordisk does not have a particularly impressive lineup or pipeline beyond diabetes and obesity, but the company could be one of the winners as the weight loss market continues to grow.
Which is the better buy? Eli Lilly generates higher revenue and earnings while growing both faster organically. Eli Lilly also has a stronger lineup -- with Zepbound's efficacy unmatched by any approved weight-loss drug so far -- and a pipeline in its core therapeutic area that is just as deep as Novo Nordisk's. True, Novo Nordisk's forward price-to-earnings of 13 looks much more attractive than Eli Lilly's 31.3. The healthcare sector's average is 17.4. However, Eli Lilly has earned a premium given its dominance in weight loss and its diversified portfolio that boasts attractive candidates in other areas. So, Eli Lilly is a much better buy right now.
Investing in dividend stocks is a great way to earn superior returns over the long run. How do we know that? According to some research, most of the S&P 500's returns over the past several decades can be attributed to reinvested dividends and compounding. This fact makes a strong case for dividend investing. However, buying shares in just any old company that happens to pay dividends isn't the way to go: They aren't all created equal. With that said, let's consider three excellent dividend stocks that are worth investors' hard-earned cash: Bristol Myers Squibb (BMY 1.44%), Merck (MRK 2.79%), and Medtronic (MDT +0.22%). Here's why these three income stocks are worth sticking with for the long term.
Image source: Getty Images.
1. Bristol Myers Squibb Bristol Myers is a leading pharmaceutical company with a deep portfolio of medicines spanning many therapeutic areas, particularly oncology. The drugmaker typically generates decent revenue and earnings, although it has encountered challenges in recent years due to patent cliffs. Bristol Myers is bouncing back, though. Newer approvals are helping push sales in the right direction. The company's first-quarter revenue climbed by 3% year over year to $11.5 billion.
Bristol Myers' growth portfolio -- composed of newer medicines that won't encounter patent cliffs anytime soon -- posted even stronger growth. Its sales were $6.2 billion, 12% higher than the year-ago period. These newer medicines should account for a larger percentage of Bristol Myers' top line within a few years and lift sales growth even higher. And while there are other patent cliffs on the horizon -- particularly that of Bristol Myers' anticoagulant, Eliquis -- the drugmaker has a deep pipeline of promising candidates that should help it overcome them.
Today's Change
(
-1.44
%) $
-0.82
Current Price
$
56.31
In fact, one of Bristol Myers' most exciting pipeline assets is a potential successor to Eliquis called milvexian. Bristol Myers thinks this medicine has multibillion-dollar potential, partly because it could avoid one key drawback of traditional anticoagulants: Bleeding risk. Bristol Myers has plenty of other candidates beyond this one. Over the long run, it should succeed in developing newer and better products while growing its sales and earnings at a decent clip.
Lastly, Bristol Myers has an attractive dividend program, with a forward yield of 4.4%. It has increased its payouts by 65.8% over the past decade. All good reasons why Bristol Myers is an attractive blue chip dividend stock to buy and hold for a long time.
2. Merck Merck has also faced challenges in recent years, particularly with one of its growth franchises -- HPV vaccines Gardasil and Gardasil 9 -- whose sales haven't been strong due to weak demand in some Asian regions. Many investors also fear that other drugmakers are coming to take Merck's crown in the cancer drug market. The company reigns supreme thanks to Keytruda, the world's best-selling cancer medicine, but several "Keytruda killers" are in development and could hit the market within a few years.
At any rate, Keytruda itself will lose patent exclusivity by the end of the decade. Is Merck still worth considering, given all these factors? My view is that it is. Here are three reasons why. First, the company has received approval for a newer, subcutaneous version of Keytruda, called Keytruda Qlex, that is much faster to administer than the original intravenous version while remaining as effective. Keytruda Qlex should extend the franchise's patent exclusivity into the next decade.
Today's Change
(
-2.79
%) $
-3.30
Current Price
$
114.90
Second, while Merck will face increased competition, it has worked hard to diversify its lineup and decrease its reliance on Keytruda. Some of the company's newer products already have an annual revenue run rate of over $1 billion. Winrevair, a medicine for pulmonary arterial hypertension first approved in 2024, generated $525 million in revenue in the first quarter, up 88% year over year. Merck's Capvaxive, a pneumonia vaccine, is performing well, too.
Third, just like any self-respecting pharmaceutical giant, Merck also has a deep pipeline that should lead to brand-new approvals and label expansions. The company has expanded its pipeline in recent years through acquisitions and now boasts exciting programs, including a highly promising influenza medicine that could address an unmet need in that area. Finally, Merck offers an attractive forward dividend yield of 3%.
The drugmaker has increased its payouts by 93.8% over the past decade. Merck should continue paying -- and raising -- its dividends for a long time, making it a good pick for income seekers.
3. Medtronic Medtronic has struggled to grow revenue at a pace satisfactory to the market in recent years. The company's profits and margins have also often disappointed. However, the medical device specialist has made significant progress in addressing its issues. Medtronic announced it would spin off its diabetes care division -- which had been a drag on operating margins -- into a stand-alone, publicly traded company.
It has also launched products that are meaningfully impacting top-line growth, and others that eventually will. Medtronic PFA (Pulse Field Ablation) franchise -- devices that use a novel technology to treat a heart problem -- has been a bright spot in recent quarters.
Today's Change
(
0.22
%) $
0.18
Current Price
$
80.38
Further, Medtronic earned approval for the Hugo system, a robotic-assisted surgery (RAS) device, last year. It will allow the company to compete with the leader in this niche, Intuitive Surgical. The RAS market is arguably underpenetrated, and although Medtronic may not take the top spot away from Intuitive Surgical -- the latter has a two-decade lead -- it could still meaningfully contribute to top-line growth.
Meanwhile, thanks to a large product portfolio and regular approvals, Medtronic generates consistent revenue and earnings. That's how it has maintained such a strong dividend program. Medtronic has increased its payouts for an impressive 48 consecutive years. The company also offers a forward yield of 3.6%. Medtronic should continue rewarding investors with regular payout increases for a long time.
Investors in Medtronic plc (MDT - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the June 18, 2026 $50.00 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?Clearly, options traders are pricing in a big move for Medtronic share, but what is the fundamental picture for the company? Currently, Medtronic is a Zacks Rank #4 (Sell) in the Medical - Products Industry that ranks in the Bottom 32% of our Zacks Industry Rank. Over the last 60 days, two analysts have increased their estimates for the current quarter, while two have revised their estimates downward. The net effect has taken our Zacks Consensus Estimate for the current quarter to move from $1.37 per share to $1.39 per share in the same time period.
Given the way analysts feel about Medtronic right now, this huge implied volatility could mean there’s a trade developing. Often times, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
Honeywell International (HON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Key Takeaways HON approved separating Aerospace into an independent public company, expected to begin operations on June 29.HON shareholders will receive one Honeywell Aerospace share for every two shares held on record.HON plans a one-for-two reverse split after the spin-off, reducing outstanding shares. Honeywell International Inc.’s (HON - Free Report) board of directors announced its approval for the planned spin-off of its Aerospace business into a separate public company. This marks a key step in the divestiture process, which is expected to be completed on June 29, 2026. Following the spin-off, Honeywell Aerospace will start operating as an independent public company.
The Aerospace business is a provider of engines, integrated avionics, systems and service solutions for aircraft manufacturers, military, space and airport operations. It also develops laser communication products for satellite communication.
Inside the HeadlinesHoneywell plans to allocate all of Honeywell Aerospace’s issued and outstanding common stock on June 29, 2026. Each HON shareholder of record as of June 15, 2026, will receive one share of the new entity for every two shares of Honeywell they hold. The distribution will take place once all specified conditions under the U.S. Securities and Exchange Commission filing are met.
It's worth noting that Honeywell Aerospace shares have commenced trading on a "when-issued’’ basis on Nasdaq under the symbol "HONAV" on June 15, 2026. However, its regular-way trading under the ticker "HONA" is expected to start on June 29, 2026.
From around June 15 to June 26, 2026, Honeywell stock will trade in two markets. One under the regular ticker “HON” with the right to receive Honeywell Aerospace shares, and another under the ticker “HONIV” without that right. Post spin-off of the Aerospace business, HON will operate as Honeywell Technologies as a premier pure-play automation company.
Also, HON announced plans to proceed with a one-for-two reverse stock split, contingent upon the completion of the Aerospace spin-off. The move will reduce the company's outstanding shares from roughly 634 million to approximately 317 million, while maintaining its Nasdaq listing under the ticker "HON." The separation and related corporate actions will restructure Honeywell's portfolio, enhance strategic focus and unlock long-term value for its shareholders.
HON's Price Performance, Valuation and Estimates
Image Source: Zacks Investment Research
Shares of the Zacks Rank #3 (Hold) company have gained 13.8% in the past six months against the industry’s decline of 2%.
From a valuation standpoint, HON is trading at a forward price-to-earnings ratio of 20.82X, above the industry’s average of 15.84X.
The Zacks Consensus Estimate for HON’s 2026 earnings has inched up 0.1% over the past 60 days.
Stocks to ConsiderSome better-ranked companies are discussed below.
GPGI, Inc. (GPGI - Free Report) currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
GPGI delivered a trailing four-quarter average earnings surprise of 25.6%. In the past 60 days, the Zacks Consensus Estimate for GPGI’s 2026 earnings has increased 20.3%.
ITT Inc. (ITT - Free Report) presently carries a Zacks Rank #2 (Buy). It has a trailing four-quarter average earnings surprise of 5.8%.
The Zacks Consensus Estimate for ITT’s 2026 earnings has increased 6.8% in the past 60 days.
Griffon Corporation (GFF - Free Report) presently carries a Zacks Rank of 2. GFF delivered a trailing four-quarter average earnings surprise of 3.3%.
In the past 60 days, the consensus estimate for Griffon’s 2026 earnings has increased 2.6%.
Key Takeaways Collins Aerospace supplies seating, cabin systems, lighting, galleys and connectivity technologies.RTX supports both new aircraft production and fleet modernization through its interior solutions portfolio.Growing demand for cabin upgrades and next-generation interior technologies supports long-term opportunities. RTX Corporation (RTX - Free Report) , through its Collins Aerospace business, continues to strengthen its position in the commercial aerospace market via advanced aircraft interior solutions. As airlines focus on enhancing passenger experience and improving operational efficiency, demand remains healthy for modern cabin technologies, seating systems, connectivity solutions and interior components. These products support both new aircraft production and fleet modernization programs, creating long-term opportunities across the aviation market.
Collins Aerospace supplies seating, cabin systems, lighting solutions, galley equipment, oxygen systems and connectivity technologies used across a wide range of commercial aircraft platforms. This diversified offering allows RTX to support airlines and aircraft manufacturers through multiple phases of an aircraft's lifecycle while benefiting from continued fleet expansion and replacement activity.
The aircraft interiors business also provides opportunities to participate in evolving airline priorities. Carriers increasingly seek solutions that improve passenger comfort, maximize cabin utilization and enhance operational performance. Through ongoing product development and engineering expertise, Collins Aerospace remains well-positioned to support these changing requirements while maintaining strong relationships with aircraft manufacturers and operators.
Commercial aerospace remains one of RTX's largest growth drivers. Through Collins Aerospace, the company serves major aircraft programs worldwide and maintains a significant installed base across global fleets. Continued demand for cabin modernization, connectivity and next-generation interior technologies could support long-term growth opportunities within RTX's commercial aerospace operations.
Companies Expanding Aircraft Interior CapabilitiesAs airlines continue investing in passenger experience and cabin modernization, aerospace suppliers are expanding their aircraft interior technologies and cabin-system offerings. Companies like Safran S.A. (SAFRY - Free Report) and The Boeing Company (BA - Free Report) are also strengthening their presence in this area.
Safran develops integrated aircraft interior solutions, including cabin monuments, galleys, lavatories and overhead storage systems, supporting commercial aircraft manufacturers and airlines worldwide.
Boeing continues expanding its cabin modification capabilities through interior upgrades, seating solutions, galley products and overhead storage enhancements that support airline fleet modernization initiatives.
Earnings Estimates for RTXThe Zacks Consensus Estimate for 2026 and 2027 earnings per share suggests year-over-year growth of 9.86% and 8.96%, respectively.
Image Source: Zacks Investment Research
RTX Stock Trading at a DiscountRTX is trading at a discount relative to the industry, with a forward 12-month price-to-sales of 2.56X compared with the industry average of 2.58X.
Image Source: Zacks Investment Research
RTX Stock Price PerformanceOver the past year, RTX shares have rallied 23.7% compared with the industry’s 3.5% growth.
Image Source: Zacks Investment Research
RTX’s Zacks RankRTX currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
RTX (RTX - Free Report) closed at $186.77 in the latest trading session, marking a +1.7% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.57%. Meanwhile, the Dow experienced a rise of 0.64%, and the technology-dominated Nasdaq saw a decrease of 1.15%.
Shares of the an aerospace and defense company have appreciated by 4.37% over the course of the past month, underperforming the Aerospace sector's gain of 8.09%, and outperforming the S&P 500's gain of 2.14%.
The upcoming earnings release of RTX will be of great interest to investors. On that day, RTX is projected to report earnings of $1.66 per share, which would represent year-over-year growth of 6.41%. Meanwhile, our latest consensus estimate is calling for revenue of $22.89 billion, up 6.07% from the prior-year quarter.
RTX's full-year Zacks Consensus Estimates are calling for earnings of $6.91 per share and revenue of $93.68 billion. These results would represent year-over-year changes of +9.86% and +5.73%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for RTX. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.05% higher. As of now, RTX holds a Zacks Rank of #3 (Hold).
Looking at its valuation, RTX is holding a Forward P/E ratio of 26.57. This valuation marks a premium compared to its industry average Forward P/E of 24.92.
We can additionally observe that RTX currently boasts a PEG ratio of 2.6. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As the market closed yesterday, the Aerospace - Defense industry was having an average PEG ratio of 1.53.
The Aerospace - Defense industry is part of the Aerospace sector. This industry, currently bearing a Zacks Industry Rank of 97, finds itself in the top 40% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
The Invesco KBW Bank ETF (KBWB +1.61%) offers a lower-cost entry into the banking sector with higher recent returns, while the First Trust Nasdaq Bank ETF (FTXO +1.34%) provides broader diversification.
Both funds target the domestic banking sector but follow different indexing methodologies to capture the industry performance. While the Invesco KBW Bank ETF tracks a market-cap-weighted index of money centers and regional banks, the First Trust Nasdaq Bank ETF uses a “smart” indexing approach focused on liquidity and fundamental factors such as volatility and growth.
Snapshot (cost & size)MetricFTXOKBWBIssuerFirst TrustInvescoExpense ratio0.6%0.35%1-yr return (as of June 8, 2026)26.2%36.0%Dividend yield1.8%2.0%Beta0.891.02AUM$290.8 million$5.6 billionBeta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
The Invesco fund is more affordable, charging an expense ratio of 0.35% compared to the 0.6% for the First Trust fund. Additionally, the Invesco fund offers a higher payout for income-seeking investors through its distribution yield.
Performance & risk comparisonMetricFTXOKBWBMax drawdown (5 yr)(46.6%)(49.3%)Growth of $1,000 over 5 years (total return)$1,367$1,523What's insideInvesco KBW Bank ETF (KBWB) focuses entirely on the financial services sector, with 26 holdings representing 100% of the portfolio. Launched in 2011, it weights its positions using a modified market-cap approach to track national money center banks and thrifts. Its largest positions include Morgan Stanley (MS +1.31%) at 9.28%, The Goldman Sachs Group (GS +1.35%) at 8.85%, and Bank of America (BAC +1.74%) at 7.84%. Over the trailing 12 months, the Invesco fund has paid $1.80 per share in dividends.
First Trust Nasdaq Bank ETF (FTXO) also maintains 100% exposure to financial services but uses a broader selection of 42 holdings. Launched in 2016, its top holdings include Citigroup (C +1.26%)at 9.04%, Bank of America at 8.05%, and JPMorgan Chase & Co. (JPM +3.66%) at 7.75%. This fund has a trailing-12-month dividend of $0.68 per share. Both ETFs prioritize U.S.-listed institutions, but FTXO includes more regional players and mid-sized banks than its larger competitor, which tends to lean toward the industry heavyweights.
For more guidance on ETF investing, check out the full guide at this link.
Which looks like the better buyThe Invesco KBW Bank ETF (KBWB) and the First Trust Nasdaq Bank ETF (FTXO) are both exchange-traded funds (ETFs) focused on the banking sector. However, they differ in some key respects. Here’s what investors need to know about each of them.
First, let’s start with KBWB. This fund, started in 2011, is focused on national money centers, leading regional banks, and thrifts. Granted, its top holdings include Goldman Sachs, Morgan Stanley, and Bank of America — giant, global banking brands; however, these mega-caps comprise only about a third of the fund’s holdings. The rest is dedicated to smaller companies. Overall, the fund offers exposure at a reasonable cost. The fund charges an expense ratio of 0.35%. Finally, the fund’s 2.0% dividend yield is solid.
Then, there’s FTXO. This fund is slightly more diversified than KBWB, with 42 holdings rather than KBWB’s 26. It also has a greater share of regional banks. As for performance, FTXO has generated a total return of 148% since 2017, with a compound annual growth rate (CAGR) of 9.8%. KBWB, by contrast, has generated a total return of 215%, with a CAGR of 12.6%. Both funds have underperformed the S&P 500, which has generated a total return of 309%, with a CAGR of 15.7%.
In summary, for investors seeking exposure to the U.S. banking sector, KBWB may be of interest due to its lower fees, higher dividend yield, and better long-term performance. However, some investors may still favor FTXO due to its greater diversification.
Morgan Stanley (MS - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Over the past month, shares of this investment bank have returned +13.1%, compared to the Zacks S&P 500 composite's +2.1% change. During this period, the Zacks Financial - Investment Bank industry, which Morgan Stanley falls in, has gained 10%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Morgan Stanley is expected to post earnings of $2.73 per share for the current quarter, representing a year-over-year change of +28.2%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.7%.
The consensus earnings estimate of $11.87 for the current fiscal year indicates a year-over-year change of +16.3%. This estimate has changed +0.2% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $12.49 indicates a change of +5.2% from what Morgan Stanley is expected to report a year ago. Over the past month, the estimate has changed +0.2%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Morgan Stanley is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Morgan Stanley, the consensus sales estimate of $18.71 billion for the current quarter points to a year-over-year change of +11.4%. The $77.26 billion and $80.79 billion estimates for the current and next fiscal years indicate changes of +9.4% and +4.6%, respectively.
Last Reported Results and Surprise HistoryMorgan Stanley reported revenues of $20.58 billion in the last reported quarter, representing a year-over-year change of +16%. EPS of $3.43 for the same period compares with $2.6 a year ago.
Compared to the Zacks Consensus Estimate of $19.85 billion, the reported revenues represent a surprise of +3.7%. The EPS surprise was +12.09%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Morgan Stanley is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Morgan Stanley. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
LONDON--(BUSINESS WIRE)--Morgan Stanley Investment Management, through investment funds managed by Morgan Stanley Real Estate Investing (MSREI), alongside Ridgeback Group (Ridgeback), announced today the acquisition of the Private Rented Sector (PRS) business of London & Quadrant Housing Trust (L&Q), which trades as Metra Living, for a total enterprise value of £1.045 billion. The transaction includes a portfolio of approximately 3,200 homes across Greater London, as well as its fully i.
NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Intuit, Inc. (“Intuit” or the “Company”) (NASDAQ: INTU). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Intuit and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 20, 2026, Intuit released its fiscal Q3 2026 financial results, which included its 2026 tax season revenue. Intuit stated that it “did not have the overall tax season we expected” and that it “faced pressure among the most price-sensitive DIY filers.” Intuit said that “[w]e [lost] on price,” and revealed that the Company needed to evolve its business model by delivering the right lineup and price points to meet simple filers’ needs at the low end. Intuit also announced that TurboTax online paying units were expected to grow by only 2% as total IRS filers were expected to decline by approximately 30 basis points, representing the “most significant industry-wide contraction since the post-COVID tax season.”
On this news, Intuit’s stock price fell $76.86 per share, or 20.02%, to close at $307.07 per share on May 21, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Stock futures are ticking higher as the market looks to add to the big gains posted on Monday following news of an Iran peace deal; SpaceX shares are poised to climb for the another session after the company's record-setting Friday IPO; the Fed will kick off its two-day meeting on interest rates; world leaders are meeting in France, with discussions focused on the next steps in securing peace in the Middle East; and GM is reportedly in talks to supply Lockheed Martin with parts for weapons. Here's what you need to know today.
Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD LiveCustomer Center
My Stock Lists
Email Preferences
Help & Support
Sign Out
Search stocks or keywords
Sections
My IBD
MARKET TREND
STOCK LISTS
STOCK RESEARCH
NEWSECONOMY
VIDEOS & PODCASTS
HOW TO INVESTEDUCATIONAL RESOURCESStoreMy Products
Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD Live
Recently Searched
State Street Among 16 Leaders New To Best Growth Stock Lists Like Big Cap 20, Stock Spotlight
Stock Market Today: Nasdaq, S&P 500 Cool Off; How Will SpaceX Impact Aerospace Stocks?
Dow Jones Futures Rise Before Warsh's Fed Debut; SpaceX Keeps Rising, Four Stocks In Buy Areas President Donald Trump on Tuesday invoked the Defense Production Act in an effort to bolster supply chains and accelerate manufacturing for key munitions. Elsewhere, General Motors stock briefly attempted to break out Tuesday on reports that the automaker is in talks to supply parts for Lockheed Martin's defense systems. President Trump on Monday invoked the Defense Production Act, according to a…
Key Takeaways Lockheed Martin is strengthening sonar capabilities to support the U.S. Navy and allied maritime security.LMT's ARCI system boosts submarine sonar processing, detection and acoustic surveillance capabilities.Lockheed Martin secured a $223.9M Navy contract for sonar engineering, development and production. Lockheed Martin (LMT - Free Report) is strengthening its sonar capabilities through advanced underwater surveillance technologies, next-generation anti-submarine warfare systems and continued support for naval modernization programs. As demand for enhanced maritime security rises, the company is expanding its sonar portfolio to support the U.S. Navy and allied nations in detecting and tracking underwater threats.
The growing focus on underwater warfare has increased the need for sophisticated sonar systems capable of improving threat detection, seabed mapping and maritime domain awareness. Modern naval operations increasingly rely on advanced sonar-equipped submarines and surface ships to identify quieter underwater threats and strengthen anti-submarine warfare readiness.
LMT continues to enhance its undersea warfare offerings through advanced Sound Navigation and Ranging (Sonar) technologies. The company plays a critical role in developing and integrating sonar systems that support submarine and surface ship missions, enabling better underwater surveillance, target tracking and situational awareness.
A major example of LMT’s sonar strength is its Acoustic Rapid Commercial Off-the-shelf Insertion system, a widely used submarine sonar platform deployed across the U.S. Navy submarine fleet. ARCI improves sonar processing performance by rapidly integrating commercial technologies, enhancing submarine detection and acoustic surveillance capabilities.
The company’s Rotary and Mission Systems business supports next-generation sonar engineering, development and production to modernize naval undersea defense. LMT recently secured a $223.9 million U.S. Navy contract modification for sonar system engineering, design, development and production support, underscoring strong demand for its advanced undersea warfare technologies.
Overall, through advanced sonar integration, submarine warfare expertise and continued modernization support, LMT is strengthening its position in the growing undersea defense market.
Other Stocks to Keep on the WatchlistOther aerospace and defense companies expanding their sonar and underwater warfare capabilities are discussed below:
RTX Corporation (RTX - Free Report) : Through its Raytheon unit, the company develops advanced sonar systems for naval applications, including the AN/AQS-20C mine-hunting sonar suite and the AN/ASQ-235 Airborne Mine Neutralization System.
Northrop Grumman Corporation (NOC - Free Report) : It provides integrated sonar solutions for submarines and surface ships, enhancing anti-submarine warfare capabilities. It also provides a high-performance minehunting system AQS-24B/C, which offers significantly improved image resolution and real-time sonar processing.
The Zacks Rundown for LMTShares of LMT have risen 10.7% in the past year compared with the industry’s 3.6% growth.
Image Source: Zacks Investment Research
The company shares are trading at a discount on a relative basis, with its forward 12-month Price/Earnings being 17.14X compared with its industry’s average of 32.69X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for LMT’s 2026 and 2027 earnings has moved south over the past 60 days.
Image Source: Zacks Investment Research
LMT stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
, /PRNewswire/ -- Lockheed Martin [NYSE: LMT] and GM Defense today announced a new collaboration to strengthen America's manufacturing and defense industrial base, facilitated by the U.S. Department of War.
Working under a memorandum of understanding (MOU), Lockheed Martin and GM Defense will explore opportunities to accelerate the delivery of critical capabilities and innovation by combining Lockheed Martin's defense production expertise with General Motors' advanced industrial capabilities in high-rate commercial manufacturing and engineering.
The collaboration will focus on three areas: strengthening defense supply chains, advancing manufacturing and design capabilities, and evaluating opportunities to expand production capacity through commercial manufacturing expertise and infrastructure. Initial efforts will include exploring ways to accelerate production readiness and apply proven commercial manufacturing approaches to support defense production requirements.
"America's security depends not only on developing advanced technologies, but on our ability to produce them quickly, reliably and at scale," said Frank St. John, chief operating officer, Lockheed Martin. "This collaboration brings together two leaders in American manufacturing and innovation to explore new ways to strengthen the defense industrial base, expand production capacity and accelerate delivery of critical capabilities for the United States and its allies."
"Working together, GM Defense and Lockheed will further strengthen American manufacturing and national defense by driving greater speed, efficiency, and innovation in the aerospace and defense sectors," said Steve duMont, president of GM Defense. "Over the coming weeks, we will be working to identify initial projects to pursue together."
The collaboration reflects growing demand for greater production capacity, supply chain resilience and manufacturing agility across the defense sector. By combining commercial and defense expertise, the companies aim to identify opportunities that can accelerate production timelines while maintaining the quality, performance and reliability standards required for mission-critical systems.
About Lockheed Martin
Lockheed Martin is a global defense technology company driving innovation and advancing scientific discovery. Our all-domain mission solutions and 21st Century Security® vision accelerate the delivery of transformative technologies to ensure those we serve always stay ahead of ready. More information at www.lockheedmartin.com.
About GM Defense LLC
GM Defense delivers integrated vehicles, power, and autonomy and connectivity solutions to global defense, security, and government markets. The exceptional reliability of GM Defense's technologies results from decades of proven performance and billions of dollars spent in independent research and development by its parent, General Motors, a world leader in global design, engineering, and manufacturing capabilities. For more information, please visit www.gmdefensellc.com.
Automaker General Motors on Tuesday announced a new partnership with defense company Lockheed Martin to scale manufacturing and expand production capabilities.
The deal was facilitated by the U.S. Department of Defense, according to Bruce Brown, GM's vice president of strategy at GM Defense, and will focus on munitions and more.
"What makes this moment especially important is that the country needs more than great technology. It also needs the capacity to build, scale and deliver reliably," Brown said on a call with reporters. "This is where GM can help. Across our company, we bring deep experience in advanced engineering, digital development, supply chain discipline and manufacturing at scale."
Lockheed Chief Operating Officer Frank St. John said it was too early to say what projects it would invest in with GM Defense.
Executives from both companies said on the call that the collaboration will allow for more growth at a time when the country is ramping up its production of defense parts.
"Together, we will explore opportunities across three important areas: improving production readiness and scalable manufacturing environments; strengthening supply chains and identifying ways to increase resilience; and applying advanced manufacturing and design approaches [that] can help improve efficiency and accelerate delivery," St. John said.
Lockheed Martin is investing $9 billion through 2030 to modernize 20 of its facilities and supply bases, St. John added. GM said it will spend $7 billion on research and development in the U.S., according to Brown.
The executives said the partnership will be focused on "high-rate manufacturing" at scale and expanding production capacity. They added that the collaboration is still in early stages and that they need to further define what the potential for future contracts may be. They are working under a memorandum of understanding.
The automaker built tanks for the country during World War II. Its GM Defense unit is one of the company's newer but fast-growing business segments, reestablished in 2017 with customers including the U.S. Army, Secret Service and NASA.
"America is stronger when two companies with deep manufacturing roots come together to help expand speed, scale and resilience in the defense industrial base. That is why Lockheed Martin and GM are announcing this collaboration," Brown said on the call.
The partnership comes as President Donald Trump has been pushing for more American manufacturing to bring more production and reshoring into the country. The U.S. has also seen its defense stockpiles fall because of the wars in Ukraine and Iran.
The White House has held discussions with Ford and GM about better supporting the country's defense industry.
— CNBC's Michael Wayland contributed to this report.
